Effect of Olopatadine on Allergic Tear Mediators

Status Completed

Clinical Trial Summary

The purpose of the research is to determine which inflammatory substances are involved in causing allergic symptoms in the eye. Allergic conjunctivitis is a common problem with symptoms of temporary redness, itching, tearing, and swelling of the eyes. Substances released by cells in the affected tissues cause allergic reactions in the eye and elsewhere in the body.

Clinical Trial Description

Ocular allergies are extremely common, affecting up to 80 million people in the USA. Our research question is:

Are there differences in inflammatory mediators and cell surface activation markers in patients undergoing seasonal allergic conjunctivitis compared to those with sight threatening disease such as Atopic Keratoconjunctivitis (AKC) and will the use of the anti-allergy eye drop, PATANOL® (olopatadine hydrochloride) affect these parameters?

Experimental Design:

Ocular surface cells (by impression cytology) and tears (via capillary tube) are collected from allergic, non-allergic, and AKC subjects undergoing an reaction induced either by seasonal allergen or topical allergen provocation (specificity and dose determined via skin testing). Ocular surface cells are evaluated for surface activation markers. Tears are evaluated for mediator content. Tears are also incubated with peripheral blood eosinophils and lymphocytes to see effects on adhesion to conjunctival epithelial cells. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00609128
Study type	Interventional
Source	University of Wisconsin, Madison
Contact
Status	Completed
Phase	N/A
Start date	September 2000
Completion date	November 2009

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03660878` - A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis	Phase 1/Phase 2
Completed	`NCT03682965` - Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study	Phase 2
Completed	`NCT01685242` - A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle	Phase 3
Completed	`NCT01697969` - Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients	Phase 4
Completed	`NCT01439815` - An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo	Phase 4
Completed	`NCT01294969` - Patient Perception Study for AL-4943A	Phase 4
Completed	`NCT01471184` - The Effects of Ectoin® Allergy Nasal Spray and Ectoin® Allergy Eye Drops Compared to Placebo	Phase 1
Recruiting	`NCT05969236` - A Study of MDI-1228_mesylate Ophthalmic Solution in Healthy Adults	Phase 1
Active, not recruiting	`NCT04619017` - Airway Immune Response to Allergens (Use Lay Language Here)	Phase 1
Not yet recruiting	`NCT01012752` - A Multicenter Study to Evaluate Safety and Efficacy of Specific Immunotherapy With Modified Allergen Extracts	Phase 3
Completed	`NCT01754766` - AGN-229666 for the Treatment of Allergic Conjunctivitis	Phase 2
Completed	`NCT01698814` - A Six-Week Safety Study of an Investigational Ophthalmic Solution	Phase 3
Completed	`NCT01443442` - Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis	Phase 4
Completed	`NCT01203540` - Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients	Phase 4
Completed	`NCT00987272` - Study of Olopatadine HCl Ophthalmic Solutions Compared to Vehicle Using the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis in Japanese Subjects	Phase 3
Completed	`NCT00769886` - Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis.	Phase 3
Completed	`NCT00534794` - Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis	Phase 4
Completed	`NCT00586625` - Safety Study for Bepotastine Besilate Ophthalmic Solution in Normal Volunteers	Phase 3
Completed	`NCT00586664` - Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis	Phase 3
Completed	`NCT00569777` - Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers	Phase 3